(Q50205173)

27 February 2018

title

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (English)

1 reference

27 February 2018

1 reference

3

C Robert

1 reference

ESMO Guidelines Committee

27 February 2018

8

object named as

ESMO Guidelines Committee

1 reference

27 February 2018

author name string

J B A G Haanen

1

1 reference

27 February 2018

F Carbonnel

2

1 reference

27 February 2018

K M Kerr

4

1 reference

27 February 2018

S Peters

5

1 reference

27 February 2018

J Larkin

6

1 reference

27 February 2018

K Jordan

7

1 reference

27 February 2018

publication date

1 July 2017

1 reference

27 February 2018

published in

Annals of Oncology

1 reference

27 February 2018

volume

28

1 reference

27 February 2018

issue

suppl_4

1 reference

27 February 2018

page(s)

iv119-iv142

1 reference

27 February 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Ipilimumab in patients with cancer and the management of dermatologic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Diverse types of dermatologic toxicities from immune checkpoint blockade therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Endocrinological side-effects of immune checkpoint inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Systematic review: colitis associated with anti-CTLA-4 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Pulmonary sarcoid-like granulomatosis induced by ipilimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Managing immune checkpoint-blocking antibody side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Management of toxicities of immune checkpoint inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Renal complications of immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Ocular and orbital side-effects of checkpoint inhibitors: a review article

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Tumor Regression and Allograft Rejection after Administration of Anti-PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Infliximab for IPILIMUMAB-Related Colitis--Letter

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX225

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDX225

1 reference

27 February 2018

1 reference

27 February 2018